R01 DA003889/DA/NIDA NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2006	1
2008	3
2009	4
2010	1
2011	5
2012	7
2013	6
2014	3
2015	4
2016	6
2017	7
2018	10
2019	6
2020	5
2021	3
2024	0

1

Human hallucinogen research: guidelines for safety.

Johnson M, Richards W, Griffiths R. Johnson M, et al. J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1. J Psychopharmacol. 2008. PMID: 18593734 Free PMC article. Review.

2

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Griffiths RR, et al. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513. J Psychopharmacol. 2016. PMID: 27909165 Free PMC article. Clinical Trial.

3

Potential Therapeutic Effects of Psilocybin.

Johnson MW, Griffiths RR. Johnson MW, et al. Neurotherapeutics. 2017 Jul;14(3):734-740. doi: 10.1007/s13311-017-0542-y. Neurotherapeutics. 2017. PMID: 28585222 Free PMC article. Review.

4

Long-term follow-up of psilocybin-facilitated smoking cessation.

Johnson MW, Garcia-Romeu A, Griffiths RR. Johnson MW, et al. Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60. doi: 10.3109/00952990.2016.1170135. Epub 2016 Jul 21. Am J Drug Alcohol Abuse. 2017. PMID: 27441452 Free PMC article. Clinical Trial.

5

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Johnson MW, et al. Pharmacol Ther. 2019 May;197:83-102. doi: 10.1016/j.pharmthera.2018.11.010. Epub 2018 Dec 4. Pharmacol Ther. 2019. PMID: 30521880 Review.

6

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.

Barrett FS, Griffiths RR. Barrett FS, et al. Curr Top Behav Neurosci. 2018;36:393-430. doi: 10.1007/7854_2017_474. Curr Top Behav Neurosci. 2018. PMID: 28401522 Free PMC article. Review.

7

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. Johnson MW, et al. Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5. Neuropharmacology. 2018. PMID: 29753748 Free PMC article. Review.

8

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.

Doss MK, Považan M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, Smith GS, Pekar JJ, Barker PB, Griffiths RR, Barrett FS. Doss MK, et al. Transl Psychiatry. 2021 Nov 8;11(1):574. doi: 10.1038/s41398-021-01706-y. Transl Psychiatry. 2021. PMID: 34750350 Free PMC article.

9

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Griffiths RR, et al. Psychopharmacology (Berl). 2011 Dec;218(4):649-65. doi: 10.1007/s00213-011-2358-5. Epub 2011 Jun 15. Psychopharmacology (Berl). 2011. PMID: 21674151 Free PMC article. Clinical Trial.

10

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Johnson MW, et al. J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11. J Psychopharmacol. 2014. PMID: 25213996 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

58 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year